Adage Capital Partners GP L.L.C. Purchases Shares of 1,292,308 Cardiff Oncology, Inc. (NASDAQ:CRDF)

Adage Capital Partners GP L.L.C. acquired a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,292,308 shares of the company's stock, valued at approximately $5,609,000. Adage Capital Partners GP L.L.C. owned 2.53% of Cardiff Oncology as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of CRDF. Bank of New York Mellon Corp raised its holdings in shares of Cardiff Oncology by 68.7% during the fourth quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock valued at $1,253,000 after acquiring an additional 117,514 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Cardiff Oncology by 5.9% in the fourth quarter. Geode Capital Management LLC now owns 982,878 shares of the company's stock valued at $4,266,000 after purchasing an additional 54,646 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Cardiff Oncology in the fourth quarter worth $222,000. Barclays PLC grew its holdings in shares of Cardiff Oncology by 291.9% during the third quarter. Barclays PLC now owns 53,089 shares of the company's stock valued at $141,000 after buying an additional 39,542 shares in the last quarter. Finally, Blair William & Co. IL raised its position in Cardiff Oncology by 14.1% during the fourth quarter. Blair William & Co. IL now owns 282,025 shares of the company's stock valued at $1,224,000 after buying an additional 34,947 shares during the period. 16.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lifted their target price on Cardiff Oncology from $13.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, February 28th.

Cardiff Oncology Price Performance

CRDF traded up $0.11 during trading on Friday, reaching $2.82. 693,525 shares of the stock traded hands, compared to its average volume of 1,122,591. The stock's 50-day simple moving average is $3.29 and its two-hundred day simple moving average is $3.48. Cardiff Oncology, Inc. has a fifty-two week low of $2.01 and a fifty-two week high of $5.64. The stock has a market cap of $187.60 million, a price-to-earnings ratio of -3.00 and a beta of 1.81.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.